MarketPeel
Insider Trading Intelligence
DG

Dov A. Md Goldstein

COYA
DIRECTOR · COYA THERAPEUTICS, INC. · CIK 0001120478
FILING MIX · LIFETIME68%/32%
BUYS
21
SELLS
10
TOTAL VALUE
$839.5K
COMPANIES
4
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
69,075
AVG SELL PX
$19.70
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 12 pending
Forward-return performance of every backtestable P/S trade by Dov A. Md Goldstein, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+33.33%+4.04%-0.70%+4.74%+5.38%
14d6+100.00%-3.08%+1.65%-4.73%-5.52%
30d6+66.67%-5.93%+1.95%-7.88%-1.82%
60d6+66.67%-7.85%-0.98%-6.87%-4.98%
90d6+66.67%-18.80%+2.04%-20.84%-20.64%
180d6(4 pending)+0.00%-11.83%+17.41%-29.24%-29.24%
1y6(4 pending)+100.00%+48.17%+24.97%+23.20%+23.20%
2y6(4 pending)+100.00%+22.80%+57.85%-35.06%-35.06%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
COYA · 10,000 shares · as of Jan 2, 2026
06,88913,77920,66827,557202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 21 buys / 10 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BIOA
BIOAGE LABS, INC.
SALE
Chief Financial Officer
3,542155,833Apr 23, 2026Apr 24, 2026View →
BIOA
BIOAGE LABS, INC.
PURCHASE
Chief Financial Officer
3,542$4.38$15.5K36,575Apr 23, 2026Apr 24, 2026View →
BIOA
BIOAGE LABS, INC.
PURCHASE
Chief Financial Officer
3,542$4.38$15.5K33,033Mar 1, 2026Mar 3, 2026View →
BIOA
BIOAGE LABS, INC.
SALE
Chief Financial Officer
3,542159,375Mar 1, 2026Mar 3, 2026View →
BIOA
BIOAGE LABS, INC.
PURCHASEGRANT
Stock grant
110,000110,000Feb 17, 2026Feb 19, 2026View →
BIOA
BIOAGE LABS, INC.
PURCHASE
Chief Financial Officer
3,541$4.38$15.5K29,491Feb 1, 2026Feb 3, 2026View →
BIOA
BIOAGE LABS, INC.
SALE
Chief Financial Officer
3,541162,917Feb 1, 2026Feb 3, 2026View →
BIOA
BIOAGE LABS, INC.
PURCHASE
Chief Financial Officer
3,542$4.38$15.5K25,950Jan 16, 2026Jan 21, 2026View →
BIOA
BIOAGE LABS, INC.
SALE
Chief Financial Officer
3,542166,458Jan 16, 2026Jan 21, 2026View →
BIOA
BIOAGE LABS, INC.
SALE10b5-1
10b5-1 plan
8,974$18.43$165.4K40,434Jan 13, 2026Jan 15, 2026View →
BIOA
BIOAGE LABS, INC.
SALE10b5-1
10b5-1 plan
1,923$21.08$40.5K22,408Jan 13, 2026Jan 15, 2026View →
BIOA
BIOAGE LABS, INC.
SALE10b5-1
10b5-1 plan
4,440$19.45$86.4K35,994Jan 13, 2026Jan 15, 2026View →
BIOA
BIOAGE LABS, INC.
SALE10b5-1
10b5-1 plan
11,663$20.54$239.5K24,331Jan 13, 2026Jan 15, 2026View →
BIOA
BIOAGE LABS, INC.
SALE
Chief Financial Officer
27,00092,587Jan 13, 2026Jan 15, 2026View →
BIOA
BIOAGE LABS, INC.
PURCHASE
Chief Financial Officer
27,000$8.39$226.5K49,408Jan 13, 2026Jan 15, 2026View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,00010,000Jan 2, 2026Jan 6, 2026View →
COYA
COYA THERAPEUTICS, INC.
SALE
17,5570Aug 18, 2025Aug 19, 2025View →
COYA
COYA THERAPEUTICS, INC.
PURCHASE
17,557$1.09$19.1K27,557Aug 18, 2025Aug 19, 2025View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 24, 2025Jun 25, 2025View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Feb 25, 2025Feb 25, 2025View →
BIOA
BIOAGE LABS, INC.
PURCHASEGRANT
Stock grant
170,000170,000Feb 18, 2025Feb 20, 2025View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Jan 1, 2025Jan 3, 2025View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jun 24, 2024Jun 26, 2024View →
COYA
COYA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,0005,000Jan 1, 2024Jan 19, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,50010,500Jun 23, 2023Jun 27, 2023View →
COYA
COYA THERAPEUTICS, INC.
PURCHASE
5,0005,000Jan 3, 2023Jan 4, 2023View →
COYA
COYA THERAPEUTICS, INC.
PURCHASE
10,00010,000Jan 3, 2023Jan 4, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,50010,500Sep 20, 2022Sep 22, 2022View →
ADMA
ADMA BIOLOGICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Feb 28, 2020Mar 3, 2020View →
ADMA
ADMA BIOLOGICS, INC.
PURCHASEGRANT
Stock grant
7,5007,500Feb 28, 2020Mar 3, 2020View →
ADMA
ADMA BIOLOGICS, INC.
PURCHASEGRANT
Stock grant
7,5007,500Feb 28, 2020May 1, 2020View →
Other insiders · COYA
Loading peer insiders…
About this filer
CIK 0001120478
ROLE
Director
PRIMARY
COYA
COMPANIES
4
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001120478DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback